[PDF] Top 20 Pasta de canola como suplemento proteico en dietas para la finalización de cerdos
Has 3828 "Pasta de canola como suplemento proteico en dietas para la finalización de cerdos" found on our website. Below are the top 20 most common "Pasta de canola como suplemento proteico en dietas para la finalización de cerdos".
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
... in combination with oncology antibody therapies. When BTH1677 enters the blood, it is bound by endogenous plasma anti-beta-glucan antibodies (ABA) resulting in complement activation and opsonization with ... See full document
9
First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
... higher efficacy in breast cancer compared to every 3-week sb-paclitaxel, improved survival has not been demonstrated in ...lacks randomized studies to compare effectiveness between the ... See full document
122
Multiple Chemotherapy-Based Combination Therapy Strategies for Advanced Lung Cancer Patients: A Systematic Review and Network Meta-Analysis
... A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive ... See full document
50
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
... the efficacy and safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus carboplatin/pemetrexed plus bevacizumab (BevCPem) in elderly patients as ... See full document
5
Phase II Trial of Celecoxib in Combination with Paclitaxel and Carboplatin in Advanced Non-Small Cell Lung Cancer
... the efficacy of cytotoxic agents through inhibition of angiogenesis, promotion of apoptosis, or other possible mechanisms (12, 13, 14, 15, 16, 17, 18, 19, ...A paclitaxel-containing regimen was selected for ... See full document
640
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
... National Cancer Institute Common Toxicity Criteria for Adverse Events version ...the bevacizumab and combination groups), symptomatic treatment was recommended without reduction of the dose of ... See full document
6
Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
... the first-line HER2-negative mBC setting? While Health Technology Assessment bodies world- wide accept PFS as a meaningful endpoint for clinical trials, progression-based outcomes are not recognized in ... See full document
12
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
... The study used a Simon 2-stage design and demonstrated an ORR (complete response + partial response) in the initial group of 11/21 (52.4%), with clinical complete response in 4.8% and partial response in 47.6%. According ... See full document
23
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
... high-dose bevacizumab (15 mg/kg) to first-line carboplatin/paclitaxel chemotherapy resulted in a modest increase in overall survival compared with chemotherapy alone ...of ... See full document
14
Current Possible Drug Therapies for Ovarian Cancer
... ICON-6 trial, randomized, double blind, phase 3 trial in platinum sensitive recurrent EOC, cediranib main- tenance showed significant improvement in PFS in the relative to control ...the first ... See full document
90
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
... All consecutive patients with histologically confirmed previously treated locally advanced or metastatic NSCLC were enrolled in this study. All patients had experienced platinum-based chemotherapy, and none of ... See full document
40
Nanomedicine review: clinical developments in liposomal applications
... the first approved class of therapeutic NPs for cancer ...biocompatible, non-toxic, and non-immunogenic composition (Bozzuto and Molinari 2015; Zamani et ...mammalian cell membrane, ... See full document
13
Novel ALK inhibitors in clinical use and development
... the trial, the agent exhibited clinical activity achieving an ORR of approximately ninety-four percent including 2 CR and 41 PR in 46 pa- tients evaluable for response ...new safety signal emerged; however ... See full document
5
Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
... that first-line icotinib treatment is a promising treatment choice for Chinese patients with advanced lung adenocarcinoma with EGFR-sensitive ... See full document
5
Original Article Clinical efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer
... clinical trial, SAIL (n=2,212), was conducted to evaluate the safety of beva- cizumab combined with first-line standard che- motherapy regimen in Chinese ...of treatment included ... See full document
22
Prospects for combining immune checkpoint blockade with PARP inhibition
... its cell- killing ability in BRCA-mutated tumors ...tumor cell death [46]. Originally, the potent anti-cancer effect of PARPi was found in BRCA1/2 deficient ovarian cancer ...breast ... See full document
79
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
... than first-degree heart block, congenital long QT syndrome or new ST segment eleva- tion or depression or new Q wave on electrocardiogram (ECG); corrected QT (QTc) ... See full document
6
<p>Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)</p>
... in combination with chemotherapy was established in a phase I trial on all NSCLC ...II trial of BVZ for NSCLC patients, 18 among six patients experiencing life-threatening pulmonary hemor- rhages, ... See full document
37
RADIOSENSITIZERS AND RADIOPROTECTORS FOR EFFECTIVE RADIATION THERAPY– A REVIEW
... and combination of nano-Pts (SOD/ catalase mimetics) may result in the reversal of cell killing effects induced by different treatment modalities, such as radiation ... See full document
80
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
... with advanced NSCLC carrying an EGFR mutation should be treated up front with gefitinib emphasising the need for EGFR status ...of treatment in advanced NSCLC, other promising biomarkers await ... See full document
8
Related subjects